Penn Medicine Lymphoma Program

Ben David, a local rabbi and father of three, shares his experience being treated for lymphoma at Penn.

Program Overview

At Penn Medicine's Abramson Cancer Center, our clinicians and researchers are leading the way in the diagnosis and treatment of lymphoma.

Our Lymphoma Program is one of the largest programs in the region and home to individuals nationally recognized for their expertise in the diagnosis and treatment of lymphoma. We provide the information, care and support you need every step of the way. 

Conditions Treated by the Lymphoma Program

We treat:

Why Penn's Lymphoma Program is Different

Our Lymphoma Program offers one of the few hematologic malignancy research programs (leukemia, lymphoma and myeloma) in the country that is approved and funded by the National Cancer Institute. In addition, our program:

  • Has a history of pioneering groundbreaking research through our discovery of the Philadelphia chromosome, which revolutionized cancer treatment
  • Pioneered the use of chemotherapy (4HC) purged bone marrow transplantation both for non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML)
  • Pioneered advanced diagnostic testing, treatments and technologies
  • Offers nationally recognized experts with years of experience in diagnosing and treating lymphoma
  • Provides support services and education programs
  • Has a reputation for sensitivity and responsiveness
  • Provides personalized attention from a multidisciplinary team that includes physician specialists in medical oncology, surgical oncology, radiation oncology and pathology. Your team will also include patient support specialists, cancer counselors and registered dietitians.
  • Developed innovative clinical trials including:
    • Immunologic approaches for lymphoma treatment
    • Pivotal clinical trials investigating combinations of monoclonal antibodies such as Rituximab and Epratuzumab, Rituximab and Galiximab, and radioimmunotherapy using Epratuzumab, Bexxar and Zevalin
    • The largest NCI initiated multi-institutional trial investigating patient specific vaccination as therapy for follicular lymphoma - The program recently developed a promising personalized vaccine therapy to prevent recurrence among certain follicular lymphoma patients. Strategies are also being developed to decrease the immune suppressive toxicities of conventional therapies for lymphoma utilizing infusion of activated autologous T-cells.

Treatments and Services Offered by the Lymphoma Program

The Abramson Cancer Center provides the latest technologies and therapies for the treatment of lymphoma in addition to a variety of helpful services.